The Phase 1 data shows best-in-class potential for soquelitinib in atopic dermatitis with durable drug-free remissions, a key differentiator from approved systemic therapies. The Phase 2 SIERRA1 trial enrollment and Angel Pharma's China trial results (late 2026) are the next catalysts. Monitor for partnership or licensing interest given the differentiated profile.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $13.66entry
- T+1 · 6mo ago −9.85%α −8.62% · $12.31
- T+5 · 6mo ago −4.21%α −3.49% · $13.08
- T+20 · 5mo ago −12.63%α −11.77% · $11.93
- T+60 · 3mo ago +0.62%α −2.97% · $13.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, showing 75% EASI 75 achievement in the 8-week cohort and durable drug-free remissions with no rebound. The biomarker data supports the novel ITK inhibition mechanism, including persistent Treg induction and JAK-STAT pathway modulation. The company is enrolling a Phase 2 SIERRA1 trial (~200 patients) and its partner Angel Pharmaceuticals is enrolling a Phase 1b/2 trial in China.
Key Facts
- Phase 1 trial enrolled 72 patients with moderate-to-severe atopic dermatitis; 35% had prior systemic therapy
- Cohort 4 (200 mg BID, 8 weeks): 75% achieved EASI 75, 25% achieved EASI 90, 33% achieved IGA 0/1
- Cohort 3 (200 mg BID, 4 weeks): 50% achieved EASI 75, 8% achieved EASI 90, 25% achieved IGA 0/1
- No disease rebound observed during drug-free follow-up (30-90 days); no rescue medications required
- Adverse events occurred in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no dose modifications
- Biomarker data shows dose-dependent reduction in Th2 cells, persistent Treg increase, and JAK-STAT pathway inhibition
- Phase 2 SIERRA1 trial enrolling ~200 patients with 12-week treatment and 90-day follow-up
- Angel Pharmaceuticals enrolling Phase 1b/2 trial in China; initial results anticipated late 2026
Financial Impact
No financial data in filing; clinical-stage biotech with no approved products or revenue
Risk Factors
- Phase 1 data is small (72 patients) and may not replicate in larger Phase 2/3 trials
- Competition from approved JAK inhibitors and biologics with established safety profiles
- No revenue or approved products; dependent on capital markets for funding
- Regulatory path uncertain; FDA may require additional trials before approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003397 |
| Exhibit: exh_991.htm | 0001171843-26-003397 |
| Document: 0001171843-26-003397-index-headers.html | 0001171843-26-003397 |
| Document: 0001171843-26-003397-index.html | 0001171843-26-003397 |
| Document: 0001171843-26-003397.txt | 0001171843-26-003397 |
Track record
15 reports on CRVS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Viewing Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers